Enhanced Uterine Cervical Device for HPV Prevention and Treatment

An advanced uterine cervical device system that optimizes HPV prevention and treatment through real-time cervical microbiome profiling, adaptive copper filament structures, and personalized treatment recommendations.

The original patent, 'Method for reducing the incidence and prevalence of human papilloma virus (HPV) and for providing protection against sexually transmitted infections,' provides a foundation for HPV prevention and treatment. However, it has limitations in terms of device customization, insertion precision, and efficacy monitoring. The new inventive concept addresses these limitations by introducing advanced features that enhance the therapeutic effect, optimize device insertion, and provide real-time feedback to users.

The enhanced uterine cervical device system comprises a programmable microcontroller that adjusts the surface area of the device between 418 mm2 to 524 mm2 based on individual cervical microbiome profiles. This ensures optimal therapeutic effect and minimizes the risk of device-related complications. The system also features a sensor-equipped guide tube for precise device insertion, reducing discomfort and ensuring proper positioning. Additionally, the device incorporates a dynamic copper filament structure that adapts to changes in cervical microbiome, providing real-time feedback to users. A wireless sensor tracks leukocyte levels and provides personalized treatment recommendations, enabling users to monitor the efficacy of the device. Furthermore, the modular design allows for interchangeable copper filament layers, enabling customized treatment protocols and minimizing the risk of device-related complications.

The new inventive concept introduces several novel features that differentiate it from the original patent. The programmable microcontroller, sensor-equipped guide tube, dynamic copper filament structure, and wireless sensor for leukocyte tracking and personalized treatment recommendations are all non-obvious advancements that significantly enhance the therapeutic effect and user experience.

Alternative embodiments of the enhanced uterine cervical device system could include different materials or structures for the copper filament, various sensor types for tracking cervical microbiome and leukocyte levels, and different communication protocols for transmitting data to users. Additionally, the system could be adapted for use in other areas of the body or for treating different types of infections or diseases.

The enhanced uterine cervical device system has significant commercial potential in the healthcare industry, particularly in the areas of women's health and infectious disease treatment. The system's ability to provide personalized treatment and real-time feedback could revolutionize the way HPV prevention and treatment are approached, offering a competitive advantage in the market. Potential target industries include pharmaceutical companies, medical device manufacturers, and healthcare providers.